Literature DB >> 25480587

Correlation of Forkhead Box c2 with subtypes and invasive ability of invasive breast cancer.

Jun Dai1, Jin-Yu Wang2, Li-Li Yang1, Ying Xiao1, Zhi-Ling Qu1, Sheng-Hui Qin1, Qiu-Rong Ruan3.   

Abstract

Forkhead Box c2 (FOXC2) is a member of forkhead/winged-helix family of transcription factors. The relationship between FOXC2 and invasive breast cancers, including basal-like breast cancer (BLBC, a subtype of breast cancer), remains to be elucidated. In this study, immunohistochemistry was used to detect the expression of FOXC2 in samples from 103 cases of invasive breast cancers and 15 cases of normal mammary glands. The relationship between FOXC2 and clinical parameters of invasive breast cancers such as patient's age, tumor size, lymph node metastasis, tumor grade, the expression of ER, PR, HER-2 and p53, and Ki-67 labeling index (LI) was evaluated. The expression of FOXC2 was detected in parent MCF7 cells, MCF cells transfected with FOXC2 expression vectors and MDA-MB-435 cells by immunohistochemistry and Western blotting. Transwell assay was used to determine the invasive ability of these cells. The results showed that FOXC2 was strongly expressed in basal epithelial cells in normal mammary glands and weakly expressed or even not expressed in glandular epithelial cells. The majority of invasive breast cancers (71.8%, 74/103) had negative or weak expression of FOXC2. However, FOXC2 was strongly expressed in 60.7% of BLBCs. Moreover, FOXC2 was related with tumor grade, p53 expression, ki-67 LI and lymph nodes metastasis. It was expressed in FOXC2-transfected MCF cells and MDA-MB-435 cells but not in parent MCF cells. Transwell assay revealed that MCF cells transfected with FOXC2 expression vectors were more aggressive than the parent MCF cells, suggesting a positive correlation between FOXC2 and the invasion of breast cancer. It was concluded that there is a significant association between FOXC2 and the metastasis of invasive breast cancer. FOXC2 may be used as a new marker for the diagnosis and prognosis prediction of different subtypes of invasive breast cancers.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25480587     DOI: 10.1007/s11596-014-1370-5

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  27 in total

Review 1.  Evolutionary genomics of the Fox genes: origin of gene families and the ancestry of gene clusters.

Authors:  Sebastian M Shimeld; Bernard Degnan; Graham N Luke
Journal:  Genomics       Date:  2009-08-10       Impact factor: 5.736

Review 2.  Assessing TP53 status in human tumours to evaluate clinical outcome.

Authors:  T Soussi; C Béroud
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

3.  Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype.

Authors:  Y Li; W Yang; Q Yang; S Zhou
Journal:  Histol Histopathol       Date:  2012-04       Impact factor: 2.303

4.  FOXC2 is a winged helix gene that counteracts obesity, hypertriglyceridemia, and diet-induced insulin resistance.

Authors:  A Cederberg; L M Grønning; B Ahrén; K Taskén; P Carlsson; S Enerbäck
Journal:  Cell       Date:  2001-09-07       Impact factor: 41.582

5.  p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells.

Authors:  Cornelia Braicu; Valentina Pileczki; Alexandru Irimie; Ioana Berindan-Neagoe
Journal:  Mol Cell Biochem       Date:  2013-06-04       Impact factor: 3.396

6.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

7.  Combinatorial regulation of endothelial gene expression by ets and forkhead transcription factors.

Authors:  Sarah De Val; Neil C Chi; Stryder M Meadows; Simon Minovitsky; Joshua P Anderson; Ian S Harris; Melissa L Ehlers; Pooja Agarwal; Axel Visel; Shan-Mei Xu; Len A Pennacchio; Inna Dubchak; Paul A Krieg; Didier Y R Stainier; Brian L Black
Journal:  Cell       Date:  2008-12-12       Impact factor: 41.582

8.  Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.

Authors:  Zheng-Sheng Wu; Qiang Wu; Jiu-Hua Yang; Hong-Qun Wang; Xiang-Dong Ding; Feng Yang; Xiao-Chun Xu
Journal:  Int J Cancer       Date:  2008-05-01       Impact factor: 7.396

9.  Foxc2 induces expression of MyoD and differentiation of the mouse myoblast cell line C2C12.

Authors:  Kazuki Omoteyama; Yoshikazu Mikami; Minoru Takagi
Journal:  Biochem Biophys Res Commun       Date:  2007-05-08       Impact factor: 3.575

10.  The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential?

Authors:  Eberhard Korsching; Jens Packeisen; Cornelia Liedtke; Daniela Hungermann; Pia Wülfing; Paul J van Diest; Burkhard Brandt; Werner Boecker; Horst Buerger
Journal:  J Pathol       Date:  2005-08       Impact factor: 7.996

View more
  1 in total

1.  Role and importance of the expression of transcription factor FOXC2 in cervical cancer.

Authors:  Jing Wang; Xiujuan Yue
Journal:  Oncol Lett       Date:  2017-09-20       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.